Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreRegorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial
Type de publicationJournal Article
Year of Publication2020
AuteursTredan O., M. Gross P, Abdeddaim C., Chabaud S., Anota A., Treilleux I., Pissaloux D., Savoye A.M, Bessard A-C.Hardy, Kalbacher E., Floquet A., Venat-Bouvet L., Lortholary A., Pop O., Frenel J-S., Cancel M., Largillier R., Louvet C., Brocard F., Ray-Coquard I.L
JournalANNALS OF ONCOLOGY
Volume31
PaginationS624-S625
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.968